SciVision Biotech Inc., founded in 2001, is a public company listed on the Taiwan Stock Exchange since 2013 (stock symbol 1786). We are a professional developer and manufacturer of high-end medical device hyaluronic acid products. Our own-developed Cross-Linked Hyaluronic Acid Platform (CHAP) and auto cross-linking technology is a breakthrough in the contemporary technology bottleneck, which makes the characteristics of hyaluronic acid products precisely controllable and widely used to produce hyaluronic acid products in different fields.

SciVision’s proprietary technology includes Cross-Linked Hyaluronic Acid Platform and auto cross-linking technology. Our auto cross-linking technology makes SciVision the only company in the world that can produce effective, medical-grade hyaluronic acid without adding any chemical substances.

SciVision Biotech has products in four high-end medical device fields, including HA dermal filler and collagen stimulator in the facial aesthetic field, absorbable adhesion barrier in the surgery field, synovial fluid supplement for the field of elderly care, and intravesical instillation in the field of urology. We provide comprehensive care for the beauty and health of the human race.

In order to meet the need for internationalization and capacity expansion, SciVision Biotech has two production sites, the Biotechnology 1 (BT1) factory and the Medical Device Plant (MD plant), both located in Kaohsiung Cianjhen Technology Industrial Park. The BT1 factory has one basement and seven floors above ground. It is qualified for Quality Management System (QMS) and ISO 13485 and complies with the US FDA and PIC/s GMP regulations. It is fully equipped with advanced automatic equipment. Excellent quality management systems and production capabilities attract cooperation from global partners.

We uphold the concept and spirit of continuous innovation, based on science, create a better vision for mankind, and help people have health, happiness, and achieve a fulfilling life.